Pharma Focus Asia

MD Anderson Breaks Ground on US$668 million New Research Facility in USA

Introduction:
The University of Texas MD Anderson Cancer Center with an investment of US$668 plans for the new cutting-edge research campus.

Features:
The new facility covering an area of 600,000-square-foot facility will accelerate collaborative cancer research at MD Anderson's South Campus.

The state-of-the-art research facility will become a catalyst for collaborative scientific breakthroughs, driving closer to the mission of eradicating cancer.

The research campus will emerge as a global focal point for cutting-edge cancer research, bringing together experts from all over the globe to fight this challenging disease.

Moreover, this groundbreaking facility will focus on scientific advancements. It is also engineered with a keen emphasis on sustainability and efficiency, ensuring an optimal working environment. 

The surrounding green spaces, connecting pathways, gathering areas, and places for reflection will establish a new benchmark for research institutions nationwide.

As an extension of the Texas Medical Centre's Helix Park, this facility will serve as a central hub for collaboration not only within MD Anderson but throughout the entire Texas Medical Centre community.

The research facility is scheduled for completion in the spring of 2026.

Specifications:
Name      Hyper Photonix
Type        New Construction
Budget    US$668 million
Year        2026
 

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference